| Wissenschaftl. Titel | An open-label, multicenter, roll-over study for patients who have completed a prior Novartis-sponsored sabatolimab (MBG453) study and are judged by the investigator to benefit from continued treatment with sabatolimab |
| Erkrankung |
Haema:
MDS:
Zweitlinie oder später
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (EudraCT) |
erstellt 30.12.2024 Data entry III CCP
geändert 30.12.2024 Data entry III CCP